Thermo Fisher Scientific has announced the launch of the CXCL10 testing service, designed to aid in the management of kidney transplant patients.

The testing service is expected to potentially make post-transplant care more convenient and less invasive for the nearly 250,000 Americans living with a kidney transplant.

It can detect the CXCL10 chemokine, which may provide valuable information faster than currently used tests.

This non-invasive urine sample collection and testing can yield results within 24 hours.

Elevated urinary CXCL10 levels have been associated with inflammation and early kidney transplant rejection, as highlighted in a recent article in Current Opinion in Organ Transplantation.

Thermo Fisher Scientific transplant services director Chris McCloskey said: “Current methods of post-transplant monitoring can represent a significant financial and physical burden for many transplant patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In keeping with our commitment to health equity, we believe this lower-cost, non-invasive testing option can expand access to care and improve patient adherence since the sample can be collected at any local clinic.”

The CXCL10 testing service by Thermo Fisher may enhance current standards of care, which sometimes lack specificity or sensitivity.

This can lead to unnecessary and invasive biopsies or delayed results that are not timely enough to influence care, thus making the treatment of rejection more challenging.

Consequently, patients may be subjected to aggressive immunosuppression regimes, increasing the risks of morbidity and mortality.

Thermo Fisher Scientific transplant diagnostics president Tina Liedtky said: “We’ve heard directly from patients that invasive biopsies and aggressive immunosuppression to prevent rejection can be incredibly detrimental to their physical and mental health.

“That’s why we’re proud to be at the forefront of the industry, leading the way with new non-invasive tests designed to improve patient outcomes and quality of life throughout the transplant journey.”

The CXCL10 assay was developed and validated by the company’s One Lambda Laboratories.

Although this laboratory-developed test is used for clinical purposes by the CLIA-certified laboratory performing the test, it has not been cleared or approved by the Food and Drug Administration as an in vitro diagnostic test.

Last October, Thermo Fisher announced its intention to acquire Swedish proteomics firm Olink for $3.1bn.

The acquisition is expected to be finalised by this year, pending customary regional conditions.